Greenwich LifeSciences, Inc. provided an update on its Phase III clinical trial, FLAMINGO-01, which is investigating the immunotherapy GLSI-100 for preventing breast cancer recurrences. The Data ...
VEON announces a $35 million share buyback, the third phase of its $100 million program, to enhance shareholder value. VEON Ltd. has announced the initiation of the third phase of its $100 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results